“Bonzyme”Whole-enzymatic method, environmental-friendly
“Bonzyme”Whole-enzymatic method, environmental-friendly

“Bonzyme”Whole-enzymatic method, environmental-friendly

Supplier of NMN Raw Materials for
Anti-aging Research in CELL Journal

Bontac keeps cultivating deeply on the field of green biosynthesis of coenzymes and nature products

Bontac is the first enterprise in the world to achieve mass production of NMN

Our Products

Product Display

NAD-ER GRADE

NAD-ER GRADE

CAS No.: 53-84-9
Purity: ≥99%

NR-Malate

NR-Malate

CAS No.:2415659-01-5
Purity:≥97.0%

NMNH

NMNH

CAS No.: 108347-85-9
Purity: ≥99.5%

NAD

NAD

CAS No.: 53-84-9
Purity: ≥99%

 NADH

NADH

CAS No.: 606-68-8
Purity: ≥98%

Stevia Sweetener (RD)

Stevia Sweetener (RD)

CAS No.: 63279-13-0
Purity: ≥95%

 NADPH

NADPH

CAS No.:2646-71-7
Purity: ≥95%

S-NAD

S-NAD

CAS No.: 4090-29-3
Purity: ≥ 95%

BONTAC is the Leader of Global Industry

What We Do

Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.

As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.

In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
more>>
BONTAC HIGHLIGHT HONORS

Bontac lnternational Patents

14

NMN Patent

90

Honor Certificate

170

Invention Patent

200

More Patents

Why Choose Us

appoinment-img

Inquiry

Our Blog

Latest News

NR: A Cardioprotective Booster via Glycolysis Activation in Low Insulin Settings

18 Jun 2024

NR: A Cardioprotective Booster via Glycolysis Activation in Low Insulin Settings

  Introduction Nicotinamide adenine dinucleotide (NAD+) metabolism is essential for maintaining normal physiological activities, and the decreased NAD+ level is related to various pathologies such as cardiac dis
Autophagy-NAD Axis as a Target for Therapeutic Interventions in NPC1 Disease

17 Jun 2024

Autophagy-NAD Axis as a Target for Therapeutic Interventions in NPC1 Disease

Introduction Targeting the autophagy-NAD axis has been reported be a viable therapeutic strategy for Niemann-Pick type C1 (NPC1) disease. The study suggests that both pharmacological rescue of autophagy deficiency and
Hello! 2024 CPHI

14 Jun 2024

Hello! 2024 CPHI

On June 19th~21st, 2024, Chemical Pharmaceutical Ingredient (CPHI) Exhibition will be held in Shanghai New International Expo Center, China. BONTAC will display premium raw materials of coenzyme and natural products
Rh2 and Ca(OH)2 Combo: Promising Treatment for Root Canal Infections

12 Jun 2024

Rh2 and Ca(OH)2 Combo: Promising Treatment for Root Canal Infections

Introduction Apical periodontitis, an inflammatory disease affecting tooth apex tissues, is triggered by oral pathogens infecting the root canal. One of the main reason for endodontic treatment failure is Enterococcus
The Possible Use of Stevioside as a Therapeutic Alternative in Amoebiasis

07 Jun 2024

The Possible Use of Stevioside as a Therapeutic Alternative in Amoebiasis

Introduction Amoebiasis has emerged as the third most common cause of death by parasites worldwide after malaria and schistosomiasis infections. According to the report of World Health Organization, over 40 milli
Transcriptome and Metabolome Profiling on the Potential of NMN/NR Against NAFLD

30 May 2024

Transcriptome and Metabolome Profiling on the Potential of NMN/NR Against NAFLD

  Introduction Disturbance in hepatic NAD+ metabolism has been manifested as a key factor in the initiation and progression of nonalcoholic fatty liver disease (NAFLD), one of the most co
Ginsenoside Rg3: A Promising Therapeutic Agent for Traumatic Brain Injury

29 May 2024

Ginsenoside Rg3: A Promising Therapeutic Agent for Traumatic Brain Injury

  Introduction According to the 2017 Commission on Traumatic Brain Injury (TBI), TBI remains one of the top three causes of injury-related death and disability up to 2030. There are 50~60
NMN Supplementation: A Shield Against Doxorubicin-Induced Multi-Organ Fibrosis

28 May 2024

NMN Supplementation: A Shield Against Doxorubicin-Induced Multi-Organ Fibrosis

  Introduction In clinical settings, doxorubicin (DOX) is an effective broad-spectrum anti-cancer drug in chemotherapy for various tumors, including hematological malignancies and solid tumors such as leu
Guarding Your Liver Against Nicotine and Coca-Cola™-Induced Steatosis with NR

27 May 2024

Guarding Your Liver Against Nicotine and Coca-Cola™-Induced Steatosis with NR

Introduction Cigarettes containing nicotine (Nic) and sugar-sweetened beverages (SSBs) with high fructose corn syrup (HFCS) have been uncovered to induce hepatic steatosis, which are the risk factors for the developme
20(S)-Ginsenoside Rh2: A Promising Adjuvant Treatment for Acute Promyelocytic Leukemia

23 May 2024

20(S)-Ginsenoside Rh2: A Promising Adjuvant Treatment for Acute Promyelocytic Leukemia

  Introduction Acute promyelocytic leukemia (APL), the M3 type of acute myeloid leukemia (AML), typically relies on all-trans retinoic acid (ATRA) as its primary treatment. While APL patients treated with

Leave Your Message